Junliang Li

Dr. Junliang Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
RWRuipeng Wang rui Wang
Ruipeng Wang rui Wang
TGTiankang Guo
Tiankang Guo
JLJunliang Li
Junliang Li
A peritoneal adhesion (PA) is a fibrotic tissue connecting the abdominal or visceral organs to the peritoneum. The formation of PAs can induce a variety of clinical diseases. However, there is currently no effective strategy for the prevention and treatment of PAs. Damage to peritoneal mesothelial cells (PMCs) is believed to cause PAs by promoting inflammation, fibrin deposition, and fibrosis formation. In the early stages of PA formation, PMCs undergo mesothelial–mesenchymal transition and have the ability to produce an extracellular matrix. The PMCs may transdifferentiate into myofibroblasts and accelerate the formation of PAs. Therefore, the aim of this review was to understand the mechanism of action of PMCs in PAs, and to offer a theoretical foundation for the treatment and prevention of PAs.

1 January 2024 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
CFChen Fu
Chen Fu
BZBangxing Zhang
Bangxing Zhang
TGTiankang Guo
Tiankang Guo
JLJunliang Li
Junliang Li
Fu C, et al. Korean J Radiol. 2024 Jan;25(1):86-102. https://doi.org/10.3348/kjr.2023.0840

9 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JLJunliang Li
Junliang Li
TGTiankang Guo
Tiankang Guo
Peritoneal metastatic cancer comprises a heterogeneous group of primary tumors that originate in the peritoneal cavity or metastasize into the peritoneal cavity from a different origin. Metastasis is a characteristic of end-stage disease, often indicative of a poor prognosis with limited treatment options. Peritoneal mesothelial cells (PMCs) are a thin layer of cells present on the surface of the peritoneum. They display differentiated characteristics in embryonic development and adults, representing the first cell layer encountering peritoneal tumors to affect their progression. PMCs have been traditionally considered a barrier to the intraperitoneal implantation and metastasis of tumors; however, recent studies indicate that PMCs can either inhibit or actively promote tumor progression through distinct mechanisms. This article presents a review of the role of PMCs in the progression of peritoneum implanted tumors, offering new ideas for therapeutic targets and related research.

29 December 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZLZhiyuan Li
Zhiyuan Li
JQJinfeng Qi
Jinfeng Qi
TGTiankang Guo
Tiankang Guo
JLJunliang Li
Junliang Li

5 December 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RZRuixi Zhou
Ruixi Zhou
TGTiankang Guo
Tiankang Guo
JLJunliang Li
Junliang Li

29 October 2024 in Immunology & Cell Biology
Verified
Journal Article
Closed access
SYShangwei Yang
Shangwei Yang
YZYanhe Zheng
Yanhe Zheng
ZPZhenjun Pu
Zhenjun Pu
HNHongyu Nian
Hongyu Nian
JLJunliang Li
Junliang Li